Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | NPY4R | P50391 | 5/20 | 0.38 |
| ▸ | NPY1R | P25929 | 3/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | NPY2R | P49146 | 2/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.35 |
| ▸ | NOS1 | P29475 | 2/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | OTC | P00480 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL604856 | 1.00 | MEN1 (0.45) | MEN1GAAKMT2AMAOAMAOB | |
| SCHEMBL8975661 | 1.00 | MEN1 (0.45) | MEN1GAAKMT2AMAOAMAOB | |
| Hydrochloric Acid SCHEMBL27482850 | 0.98 | MEN1 (0.44) | MEN1GAAKMT2AMAOAMAOB | |
| Hydrochloric Acid SCHEMBL8376792 | 0.98 | MEN1 (0.44) | MEN1GAAKMT2AMAOAMAOB | |
| Hydrochloric Acid SCHEMBL29398231 | 0.98 | MEN1 (0.44) | MEN1GAAKMT2AMAOAMAOB | |
| SCHEMBL5847744 | 0.89 | MEN1 (0.41) | MEN1GAAKMT2AMAOAMAOB | |
| SCHEMBL20468063 | 0.88 | MEN1 (0.37) | MEN1GAAKMT2AMAOAMAOB | |
| SCHEMBL14414714 | 0.88 | MEN1 (0.45) | MEN1GAAKMT2AMAOAMAOB | |
| SCHEMBL14090836 | 0.88 | MEN1 (0.45) | MEN1GAAKMT2AMAOAMAOB | |
| SCHEMBL30860176 | 0.88 | MEN1 (0.47) | MEN1GAAKMT2AMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120051554-A | Lipid removal in detergents | 诺维信公司 | 2025-05-27 | — | — | CN | disclosed |
| US-8785488-B2 | Triazole and imidazole derivatives for use as TGR5 agonists in the treatment of diabetes and obesity | EXELIXIS PATENT COMPANY LLC (US) | 2014-07-22 | — | — | US | disclosed |
| US-20120040985-A1 | TRIAZOLE AND IMIDAZOLE DERIVATIVES FOR USE AS TGR5 AGONISTS IN THE TREATMENT OF DIABETES AND OBESITY | EXELIXIS PATENT COMPANY LLC (US) | 2012-02-16 | — | — | US | disclosed |
| US-20110263539-A1 | SHIP 1 MODULATOR COMPOUNDS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2011-10-27 | — | — | US | disclosed |
| US-20100323990-A1 | SHIP 1 MODULATOR PRODRUGS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2010-12-23 | — | — | US | disclosed |
| US-20100168225-A1 | Small-Molecule Hepatitis C Virus (HCV) NS3/4A Serine Protease Inhibitors | JEAN FRANCOIS | 2010-07-01 | — | — | US | disclosed |
| EP-1135398-A1 | CYANOPHOSPHONAMIDES AND METHOD FOR PREPARATION | Monsanto Technology LLC (US) | 2001-09-26 | — | — | EP | disclosed |
| US-6218563-B1 | Cyanophosphonamides and method for preparation | MONSANTO COMPANY | 2001-04-17 | — | — | US | disclosed |
| WO-2000032611-A1 | CYANOPHOSPHONAMIDES AND METHOD FOR PREPARATION | MONSANTO TECHNOLOGY LLC (US) | 2000-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168225-A1 | Small-Molecule Hepatitis C Virus (HCV) NS3/4A Serine Protease Inhibitors | SRR, HAVCR2, CBR3 | MEN1 4766/4885GAA 2230/4885KMT2A 3192/4885 |
| US-20100323990-A1 | SHIP 1 MODULATOR PRODRUGS | PPM1D, PPM1G, PPM1F | MEN1 846/4885GAA 3237/4885KMT2A 1708/4885 |
| US-20110263539-A1 | SHIP 1 MODULATOR COMPOUNDS | PPM1F, PPM1D, PPP1R1B | MEN1 983/4885GAA 3335/4885KMT2A 2048/4885 |
| US-20120040985-A1 | TRIAZOLE AND IMIDAZOLE DERIVATIVES FOR USE AS TGR5 AGONISTS IN THE TREATMENT OF DIABETES AND OBESITY | GPR119, GLP1R, GCGR | MEN1 4058/4885GAA 1941/4885KMT2A 3949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.